Soboll Gisela, Hussey Stephen B, Minke Jules M, Landolt Gabriele A, Hunter James S, Jagannatha Shyla, Lunn David P
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523, USA.
Merial S.A.S., 254 rue Marcel Merieux, 69007 Lyon, France.
Vet Immunol Immunopathol. 2010 May 15;135(1-2):100-107. doi: 10.1016/j.vetimm.2009.11.007. Epub 2009 Nov 24.
Equine influenza virus remains an important problem in horses despite extensive use of vaccination. Efficacy of equine influenza vaccination depends on the onset and duration of protective immunity, and appropriate strain specificity of the immune response. This study was designed to test the protective immunity resulting from vaccination with the North American commercial ALVAC equine influenza vaccine (RECOMBITEK Influenza, Merial, USA)(1) against challenge with American lineage influenza viruses. In experiment 1, 12 ponies were vaccinated twice, at a 35 day interval, using the ALVAC-influenza vaccine expressing the HA genes of influenza A/eq/Newmarket/2/93 and A/eq/Kentucky/94 (H3N8), and 11 ponies served as unvaccinated controls. Six months after the second vaccination, all ponies were challenged with A/eq/Kentucky/91. In experiment 2, 10 ponies received one dose of the ALVAC-influenza vaccine, 10 ponies served as unvaccinated controls, and all ponies were challenge infected with A/equine/Ohio/03, 14 days after vaccination. Parameters studied included serological responses, and clinical disease and nasal viral shedding following challenge infection. In experiment 1, following the two-dose regimen, vaccinated ponies generated high titered anti-influenza virus IgGa and IgGb antibody responses to vaccination and demonstrated statistically significant clinical and virological protection to challenge infection compared to controls. Infection with A/eq/Kentucky/91 produced unusually severe signs in ponies in the control group, requiring therapy with NSAID's and antibiotics, and leading to the euthanasia of one pony. In experiment 2 following the one-dose regimen, vaccinates generated IgGa responses pre-challenge, and anamnestic IgGa and IgGb responses after challenge. Vaccinates demonstrated statistically significant clinical and virological protection to challenge infection compared to controls. The results of this study clearly demonstrate the early onset, and 6-month duration of protective immunity resulting from ALVAC-influenza vaccination against challenge with American lineage equine influenza viruses.
尽管广泛使用疫苗接种,但马流感病毒仍是马匹面临的一个重要问题。马流感疫苗接种的效果取决于保护性免疫的起始和持续时间,以及免疫反应的适当毒株特异性。本研究旨在测试用北美商业ALVAC马流感疫苗(RECOMBITEK流感,美国梅里亚公司)(1) 接种后对美国谱系流感病毒攻击产生的保护性免疫。在实验1中,12匹小马间隔35天接种两次ALVAC流感疫苗,该疫苗表达甲型流感病毒/马/纽马克特/2/93和甲型流感病毒/马/肯塔基/94(H3N8)的血凝素(HA)基因,11匹小马作为未接种疫苗的对照。第二次接种疫苗6个月后,所有小马均用甲型流感病毒/马/肯塔基/91攻击。在实验2中,10匹小马接种一剂ALVAC流感疫苗,10匹小马作为未接种疫苗的对照,所有小马在接种疫苗14天后用甲型流感病毒/马/俄亥俄/03攻击感染。研究的参数包括血清学反应、攻击感染后的临床疾病和鼻腔病毒排出情况。在实验1中,采用两剂接种方案后,接种疫苗的小马对疫苗接种产生了高滴度的抗流感病毒IgGa和IgGb抗体反应,与对照组相比,对攻击感染表现出统计学上显著的临床和病毒学保护。对照组中感染甲型流感病毒/马/肯塔基/91的小马出现了异常严重的症状,需要用非甾体抗炎药和抗生素治疗,导致一匹小马安乐死。在实验2中,采用一剂接种方案后,接种疫苗的小马在攻击前产生了IgGa反应,攻击后产生了回忆性IgGa和IgGb反应。与对照组相比,接种疫苗的小马对攻击感染表现出统计学上显著的临床和病毒学保护。本研究结果清楚地证明了ALVAC流感疫苗接种对美国谱系马流感病毒攻击产生的保护性免疫的早期起始和6个月持续时间。